US › Healthcare

Cellectar Biosciences Inc (CLRB)

US · Healthcare · Biotechnology

$2.40+2.13%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.9M

EPS

$-0.57

EPS estimate

$-0.55

EPS came in at -0.57 against a street estimate of -0.55 — a miss of 3.6%.

Key statistics

Market cap

$21.8M

Forward P/E

0.0

P/B

0.74

Book value

$3.62

EPS (TTM)

$-2.17

52-week high

$6.52

52-week low

$2.20

50-day MA

$2.56

200-day MA

$2.93

Beta

0.56

Analyst view

Analysts rate Cellectar Biosciences Inc a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $11.50.

Shareholding

Insiders

1.75%

Institutions

34.71%

Largest institutional holders

Fund	Stake
Caligan Partners LP	4.97%
Empery Asset Management, LP	2.01%
Diadema Partners LP	1.46%
Bleichroeder LP	1.06%
Vanguard Capital Management, LLC	0.87%
Geode Capital Management, LLC	0.56%
Sequoia Financial Advisors LLC	0.23%
Vanguard Fiduciary Trust Co	0.18%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cellectar Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.